

TABLE 1 Patient and transplant characteristics

<b>Variable</b>	<b>N=183</b>	
<b>Gender</b>	<b>N</b>	<b>%</b>
Male	103	56.3
Female	80	43.7
<b>Sub-Disease</b>		
Sickle cell disease	44	24.0
Severe aplastic anemia	40	21.9
Primary immune deficiency	27	14.8
Thalassemia	21	11.5
Bone marrow failure syndromes	15	8.2
Severe combined immune deficiency	17	9.3
Hemophagocytic lymphistiocytosis	9	4.9
Adenoleukodystrophy	3	1.6
Hurlers	3	1.6
Other	4	2.2
<b>Age by Groups</b>		
<3 years of age	53	28.9
3-9 years of age	57	31.1
10-17 years of age	62	33.9
18 and older	11	6.0
<b>Race</b>		
White	104	56.8
Black	62	33.9
Asian	8	4.4
Unknown	9	4.9
<b>Recipient CMV Serology</b>		
Negative	75	41.5
Positive	104	56.8
Unknown/Indeterminate/Other	3	1.6
<b>Performance Score (Lansky/Karnofsky) at Transplant</b>		
80 or lower	35	19.1
≥ 90	143	78.1
Missing	5	2.7
<b>Cumulative Number of Comorbidities Prior to Transplant</b>		
0 - 1	149	81.4
2 or more	33	18.0

Missing	1	0.5
<b>Stem Cell Source</b>		
Bone marrow	128	69.9
Peripheral blood	18	9.8
Umbilical cord blood	34	18.6
Other (combination of sources)	3	1.6
<b>Donor Relation</b>		
Related	98	53.6
Unrelated	85	46.4
<b>HLA Match</b>		
Fully matched (8/8 BM/PB or 6/6 UCB)	120	65.6
Mismatched (<8/8 BM/PB or <6/6 UCB)	57	31.1
Missing	6	3.3
<b>HLA Match/Relation/Source</b>		
Matched related donor	71	38.8
Matched unrelated donor (8/8)	36	19.7
Mismatched unrelated donor (<8/8)	16	8.7
Mismatched related donor/haplo	22	12.0
Mismatched UCB (<6/6)	19	10.4
Fully matched UCB (6/6)	13	7.1
Unknow HLA match	6	3.3
<b>Donor - Recipient Sex Match</b>		
Sex matched	83	45.4
Sex mismatched	90	49.2
Missing	10	5.5
<b>Donor - Recipient CMV Antibody Match</b>		
CMV donor-recipient antibodies matched	119	65.0
CMV donor-recipient antibodies mismatched	55	30.1
Missing	9	4.9
<b>Conditioning Regimens</b>		
Busufan and cyclophosphamide ± serotherapy	15	8.2
Busulfan and fludarabine ± serotherapy	18	9.8
Melphalan, fludarabine and thiotepa ± serotherapy±rituximab	47	25.7
Fludarabine and melphalan ± serotherapy±rituximab	35	19.1

Cyclophosphamide ±ATG	16	8.7
Total body irradiation, rabbit ATG, cyclophosphamide,fludarabine ±thiotepa	14	7.6
Busulfan, cyclophosphamide, fludarabine ±serotherapy	12	6.6
ATG alone	1	0.5
Cyclophosphamide and fludarabine±serotherapy	13	7.1
Preparative regimen not used	7	3.8
Other regimen	4	2.2
Unknown regimen	1	0.5
<b>Intensity of Conditioning regimens</b>		
Myeloablative	101	55.2
Non-myeloablative	38	20.8
Reduced intensity	36	19.7
Conditioning regimen not used/unknown regimen	8	4.4
<b>Serotherapy</b>		
ATG	101	55.2
Alemtuzumab	63	34.4
Neither	17	9.3
Missing	2	1.1
<b>Rituximab Used</b>		
No	133	72.7
Yes	42	23.0
Missing	8	4.3
<b>Year of Transplant</b>		
2010 - 2012	48	26.2
2013 - 2015	61	33.3
2016 - 2019	74	40.4
<b>Center</b>		
1	66	36.1
2	11	6.0
3	32	17.5
4	48	26.2
5	26	14.2

PB= peripheral blood

BM= bone marrow

UCB= umbilical cord blood

ATG = anti-thymocyte globulin

